COMMUNIQUÉS West-GlobeNewswire

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025
10/01/2025
In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA on confirmatory [...]
ADARx Pharmaceuticals to Present at the J.P. Morgan 43ʳᵈ Annual Healthcare Conference
10/01/2025
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, [...]
Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD
10/01/2025
Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical proof of concept of [...]
OneMedNet Regains Compliance with NASDAQ Minimum Bid Price Requirements
10/01/2025
MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World [...]
Yerbaé Expands Distribution with Four New Partnerships, Creating Synergies with Safety Shot's Operations
10/01/2025
SCOTTSDALE, Ariz., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a plant-based functional beverage company, announced today new partnerships with [...]
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors
10/01/2025
New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a [...]
IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues
10/01/2025
Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 million [...]
TOMI Environmental Solutions Positioned to Address Growing Global Disease Threats with SteraMist Technology
10/01/2025
Company Expands Reach to Government, Commercial Entities, and School Districts Amid Rising Concerns Over Spread of Respiratory Viruses such as RSV, HMPV, and H5N1 FREDERICK, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- TOMI [...]
NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million
10/01/2025
First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue Management to Host Virtual Investor Webinar Today at 11:00 a [...]
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock
10/01/2025
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies [...]
InflammX Therapeutics Announces Option Agreement with Bausch + Lomb
10/01/2025
TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet needs, announced [...]
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
10/01/2025
Marks a step forward in b roadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH) , atypical hemolytic uremic syndrome ( aHUS ) and generalized myasthenia gravis ( gMG ) in the U . S . P [...]
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
10/01/2025
LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody ® First-in-human study enrolling adult patients with CD123-expressing AML or MDS Initial Phase 1 data read-out expected by year-end 2025 UTRECHT, The [...]
OrthoPediatrics Corp. Announces Expansion of Specialty Bracing Division
10/01/2025
WARSAW, Ind., Jan. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
10/01/2025
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to [...]
NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
10/01/2025
BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) [...]
RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025
10/01/2025
MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its key [...]
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
10/01/2025
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE [...]
World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering
10/01/2025
By adding Canada and the entire Latin America region, including Mexico, WODA completes its full global commercialization offering for rare and specialty therapies. With two new members - Innovative Medicines Group and [...]

Pages